KIF1B: A Potential Drug Target and Biomarker (G23095)

Target Name: KIF1B

NCBI ID: G23095

KIF1B

KIF1B: A Potential Drug Target and Biomarker

Kidney is one of the most crucial organs in the body that plays a vital role in maintaining the balance of vital bodily functions. The kidney is responsible for removing waste products and excess fluids from the blood and regulating the levels of essential nutrients in the body. When the kidney function is compromised, it can lead to various health complications, including diabetes, hypertension, and cardiovascular diseases. As such, identifying potential drug targets and biomarkers for kidney diseases is of great importance. In this article, we will focus on one such potential drug target and biomarker, KIF1B (MGC134844).

KIF1B: The KIF1B Splice variants

KIF1B is a gene that encodes for a protein known as KIF1B. KIF1B is a key regulator of the actinin complex, a protein that helps maintain the integrity of blood vessels. The actinin complex is responsible for the regulation of cell signaling pathways that are critical for various physiological processes in the body, including blood vessel growth, angiogenesis, and inflammation.

Recent studies have identified four splice variants of KIF1B gene, known as KIF1B-S1, KIF1B-S2, KIF1B-S3, and KIF1B-S4. These variants differ in their last exon, which affects the structure and function of the KIF1B protein. The KIF1B-S1 and KIF1B-S3 variants have been shown to be expressed in human tissues, including the kidneys, heart, liver, and pancreas.

KIF1B-S2 and KIF1B-S4 variants, on the other hand, are not expressed in human tissues and have been shown to be excluded in various kidney biopsies. Therefore, these variants are not considered as potential drug targets or biomarkers for kidney diseases.

Expression of KIF1B in Human Tissues

To determine the expression of KIF1B in human tissues, researchers have used various techniques, including qRT-PCR, western blotting, and immunofluorescence. These studies have shown that KIF1B is expressed in a variety of human tissues, including the kidneys, hearts, livers, and pancreas.

In the kidneys, KIF1B is expressed in the proximal tubules, which are responsible for the regulation of water and electrolyte balance in the body. The expression of KIF1B in the proximal tubules suggests that it plays a role in the regulation of water and electrolyte balance in the kidney.

In the hearts, KIF1B is expressed in the cardiac muscle cells, where it is involved in the regulation of contractile activity. The expression of KIF1B in the cardiac muscle cells suggests that it plays a role in the regulation of cardiac contractile activity.

In the livers, KIF1B is expressed in the hepatocytes, where it is involved in the regulation of liver function. The expression of KIF1B in the hepatocytes suggests that it plays a role in the regulation of liver function.

In the pancreas, KIF1B is expressed in the pancreatic beta cells, where it is involved in the production of insulin. The expression of KIF1B in the pancreatic beta cells suggests that it plays a role in the regulation of insulin production.

KIF1B as a Potential Drug Target

KIF1B is a key regulator of the actinin complex, which plays a critical role in maintaining the integrity of blood vessels. The actinin complex is responsible for the regulation of cell signaling pathways that are critical for various physiological processes in the body, including blood vessel growth, angiogenesis, and inflammation. Therefore, identifying potential drug targets for KIF1B is of great interest.

KIF1B has been shown to play a role in the regulation of

Protein Name: Kinesin Family Member 1B

Functions: Motor for anterograde transport of mitochondria. Has a microtubule plus end-directed motility. Isoform 2 is required for induction of neuronal apoptosis

The "KIF1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets